Nogacid

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nogacid

What is Nogacid?

Nogacid is a pharmaceutical medication classified as a proton pump inhibitor (PPI). Its primary function is to reduce the production of stomach acid by targeting the biochemical pumps located in the lining of the stomach wall. By inhibiting these pumps, the medication effectively lowers the acidity of gastric juices.

Therapeutic Use

This medication is primarily utilized in the management of conditions where the reduction of gastric acid is necessary for symptom relief or tissue healing. It is commonly used to treat gastroesophageal reflux disease (GERD), a condition where stomach acid frequently flows back into the esophagus, causing irritation.

Additionally, it is indicated for the treatment of gastric and duodenal ulcers. By maintaining a less acidic environment in the stomach, Nogacid allows the mucosal lining to recover and prevents the formation of new ulcerations.

Mechanism of Action

The active component in Nogacid works by binding to the hydrogen-potassium ATPase enzyme system, often referred to as the "proton pump." This enzyme is the final step in the acid secretion process. Unlike other classes of acid-reducing medications that block only one trigger for acid production, PPIs like Nogacid provide a more comprehensive suppression of acid by shutting down the pumps themselves.

Regulatory References

  1. Omeprazole on WHO EML

What side effects are possible with Nogacid?

Possible Side Effects and Safety Information

The safety profile of Nogacid (Omeprazole) is established through regulatory classification, grouping adverse reactions by frequency and affected physiological system. The most Common Adverse Reactions (occurring in 1 to 10 users in 100) are typically related to the Gastrointestinal system and Nervous System disorders, including headache, abdominal pain, diarrhea, nausea, and flatulence.


Adverse effects classified as Uncommon (occurring in 1 to 10 users in 1,000) may include dizziness, somnolence, insomnia, or elevated liver enzymes. Rare effects (occurring in 1 to 10 users in 10,000) include hypersensitivity reactions, blurred vision, and changes in blood cell counts, such as leukopenia.


Serious Adverse Reactions and Contextual Safety

Official regulatory documents note reports of Serious Adverse Reactions (SARs), including specific, rare conditions such as Acute Tubulointerstitial Nephritis and severe cutaneous reactions like Stevens-Johnson Syndrome (SJS). The use of Omeprazole for long-term exposure (typically one year or more) is associated with safety considerations, including an increased risk of bone fractures (hip, wrist, spine) and the development of Hypomagnesaemia (low magnesium levels).

Specific safety statements exist for certain populations: consideration of a dose adjustment is warranted for patients with severe hepatic impairment. Furthermore, the medicine may interfere with certain laboratory tests by increasing Chromogranin A (CgA) levels, a factor relevant for neuroendocrine tumor investigations. This safety structure outlines the officially documented risk profile, focusing on descriptive regulatory data.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Nogacid (Omeprazole) overdose is based on documented clinical experience and mandated emergency actions. Overdose is generally described as not life-threatening, although specific symptoms may occur following excessive intake.

Documented Manifestations and Required Actions

Domain Official Regulatory Statement
Overdose Manifestations Symptoms reported include nausea, vomiting, diarrhea, abdominal pain, headache, confusion, drowsiness, blurred vision, and tachycardia (fast heart rate).
Help-Seeking Requirement Individuals must seek immediate medical attention and contact a Poison Help line or emergency services if an overdose is suspected.
Antidote Availability No specific antidote is known for Omeprazole overdose.

Supportive Management

Management of a suspected overdose must be symptomatic and supportive. Regulatory documents state that treatment may involve close monitoring of the patient's condition. Procedures may include the administration of activated charcoal to help reduce the absorption of the substance.

Conclusion on Regulatory Profile

The documented profile guides immediate actions: because no specific antidote exists, treatment focuses on supportive care for the transient symptoms presented. Emergency medical help is required for suspected overdose to ensure close clinical observation.

Therapeutic Uses of Nogacid

What Nogacid Treats: Main Uses and Benefits

Nogacid is commonly used across domains where additional symptomatic support is needed for conditions presenting with systemic or localized discomfort related to excessive stomach acid. The medication is applied for conditions including Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, duodenal and gastric ulcers, and Zollinger-Ellison Syndrome.

Symptom Relief and Healing

The medication is applied in addressing the persistent burning sensation of heartburn and acid regurgitation, which are symptoms that interfere with daily functioning. It is also relevant in conditions characterized by periods of heightened symptoms such as active peptic ulcers, where supportive relief is appropriate for conditions involving inflammatory or irritative processes. This assistance may help patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.


Quick Fact: Relief for Acid Reflux

Feature Description
Target Symptoms Heartburn, Acid Regurgitation, Acid-related Pain
Main Benefit Contributes to eased symptom burden, Support for conditions involving inflammatory or irritative processes
Key Indications GERD, Peptic Ulcer Disease, Erosive Esophagitis
Use Context Applied in settings marked by temporary physiological imbalance, relevant when supportive symptom management is appropriate

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

This information details the officially documented eligibility and non-eligibility criteria for Nogacid, which contains the active ingredient omeprazole. The combination product Nogacid D, containing omeprazole and domperidone, has additional restrictions.

Contraindications and Exclusions

Category Nogacid (Omeprazole) Nogacid D (Omeprazole + Domperidone)
Absolute Contraindication Known hypersensitivity to omeprazole or other substituted benzimidazoles. Hypersensitivity to active ingredients; Severe liver impairment; Pre-existing cardiac risk factors (e.g., QTc prolongation); Gastrointestinal hemorrhage, obstruction, or perforation.
Drug-Specific Exclusion Concomitant use with nelfinavir is generally prohibited. Concomitant use with strong CYP3A4 inhibitors is contraindicated due to cardiac risk.

Special Population Eligibility

  • Age-Related Rules: Omeprazole is established for specific use in pediatric patients one year of age and older. Use in infants under one month is not established. Nogacid D is typically restricted to adults.
  • Hepatic Impairment: Patients with severe liver impairment may require dose limitation for omeprazole due to altered drug clearance.
  • Pregnancy and Lactation: Use during pregnancy is permitted only if the benefit is considered to outweigh the potential risk. Breastfeeding is not recommended for the combination product due to excretion into breast milk and safety concerns, while omeprazole monotherapy is preferred if necessary.

What should I know about interactions with other medicines?

The use of Nogacid (omeprazole) may result in clinically significant interactions with a number of other medicines, primarily due to two distinct mechanisms.

Impact on Drug Absorption

Nogacid, a proton pump inhibitor, significantly reduces gastric acid production, which can alter the absorption of medicines whose effectiveness relies on an acidic stomach environment. This change may lead to lower therapeutic concentrations, effectively reducing the action of co-administered drugs. Combating this effect, concomitant use with the antiretroviral Nelfinavir is contraindicated, and use with Atazanavir and the antifungal Posaconazole is generally avoided.

Impact on Drug Metabolism

Nogacid is an inhibitor of the CYP2C19 enzyme system and can moderately inhibit CYP3A4, two enzymes responsible for metabolizing many drugs in the liver. This inhibition can increase the systemic exposure of medicines metabolized by these pathways. Close monitoring and potential dose adjustments are necessary for medicines such as the anticoagulant Warfarin, the antiarrhythmic Digoxin, and the anti-epileptic Phenytoin.

Additionally, caution is required when using Nogacid with high-dose Methotrexate, as the combination may lead to increased methotrexate levels and potential toxicity. Nogacid can also interfere with certain diagnostic laboratory tests, such as those for Neuroendocrine Tumors.

Mechanism of Action

Irreversible H^+/ K^+-ATPase Enzyme Inhibition

Nogacid's mechanism is defined by its action as an irreversible inhibitor of the H^+/ K^+-ATPase enzyme, or Proton Pump, the final molecular structure responsible for releasing acid ( H^+ ions) into the stomach. The drug's active form achieves this by forming a stable covalent bond with specific residues on the pump, irreversibly modifying the enzyme's structure, which stops the final pathway for H^+ ion exchange.

pH-Triggered Activation and Targeted Specificity

The molecule is a pro-drug that utilizes the highly acidic environment within the parietal cell's secretory canaliculi to undergo a chemical transformation into its potent inhibitory form. This pH-dependent activation ensures the active component is generated and concentrated at the site of acid production, enabling selective action against the target enzyme.

⏱️ Sustained Effect and Biological Constraint

Because the inhibition is irreversible, the prolonged duration of the drug's effect is only overcome by the biological synthesis of new H^+/ K^+-ATPase molecules by the parietal cell, a process that takes approximately 18 to 24 hours. This sustained action leads to a sustained elevation of intragastric pH by maintaining the acid-producing machinery in a disabled state. This mechanism provides the biological basis for the drug's sustained effect on gastric acidity.

Dosage and Administration Information

Official Administration Guidelines

Nogacid is an oral medication, typically available as delayed-release capsules (10 mg, 20 mg, 40 mg) or granules for oral suspension. The administration instructions are designed to protect the active ingredient until it reaches its absorption site.

Usage Parameter Instruction Primary Dose
Timing & Frequency Once daily, before a meal, preferably in the morning. Divided doses are required for daily doses over 80 mg in certain pathological conditions. 20 mg once daily (Duodenal Ulcer, GERD)
Course Duration Short-term courses typically last 4 to 8 weeks. Long-term use (up to 12 months) may be indicated for the maintenance of healing. 4-8 weeks (Gastric Ulcer)

For proper use, the capsule or the enteric-coated pellets must be swallowed whole and must not be chewed or crushed. If swallowing is difficult, the pellets may be mixed with a tablespoon of soft food, such as applesauce, or a slightly acidic fluid and swallowed immediately.

Special Populations: Dose adjustments are recommended for patients with severe hepatic impairment, where a maximum dose of 10 mg to 20 mg once daily is typically appropriate. No dose adjustment is generally required for older adults or those with renal impairment. If a dose is missed, patients should skip the missed dose if the next scheduled dose is nearly due and not take two doses at one time.

Recent Clinical Evidence

Research evidence / Overview of studies for Nogacid


Evidence Supporting Use in GERD and Esophageal Healing

Studies used in research exploring how symptoms change over time for Gastroesophageal Reflux Disease (GERD) include many short-term randomized controlled trials (RCTs). These studies typically involved adult populations and measured outcomes related to physical discomfort, such as heartburn and acid regurgitation, and examined changes in patient-reported outcomes over defined time intervals. Trials also included pediatric populations (children ge 1 year of age).

For Erosive Esophagitis (EE), a condition where the esophagus shows tissue damage, clinical trials were applied in research contexts specifically measuring the endoscopic rates of change in tissue status—that is, the proportion of patients whose mucosal damage was confirmed via endoscopy. Longer-term follow-up research was conducted to measure the non-recurrence of mucosal damage. However, findings apply only to the populations studied. Evidence remains limited and heterogeneous concerning how measurements of symptomatic change compare to those observed with other acid-suppressing agents.


Research on Ulcer Healing and Bacterial Eradication

The medicine was evaluated in studies examining duodenal and gastric ulcers. The research examined rates of change in tissue status, often confirmed through endoscopy or X-rays, over defined short time intervals. Further research explored the rates of recurrence of the ulcer in patients after the initial change phase.

Research examined the role of the medicine as part of combination therapy when studying the eradication of the Helicobacter pylori (H. pylori) bacterium, which is associated with many peptic ulcers. In these research scenarios, the studies monitored outcomes related to bacterial clearance and measured ulcer recurrence following bacterial clearance. Data show patterns related to bacterial eradication rates, but the measured eradication rates may vary based on regional antibiotic resistance patterns.


Key Uncertainties and Identified Evidence Gaps

One key limitation is that follow-up durations for many controlled studies were limited, particularly when examining outcomes associated with use over many years. This means long-term patient outcomes are not fully established based on controlled trial data. Furthermore, findings apply only to the populations studied in the original clinical trials. Evidence quality varies across studies, particularly for long-term use and rarer conditions where the research relies on small sample sizes or observational data.

Frequently Asked Questions (FAQ)

Common questions about Nogacid (FAQ)


Q: How quickly should I expect Nogacid to start working?

Studies and official information indicate that the maximum suppression of stomach acid secretion typically reaches its full effect, or 'plateau,' after approximately four days of consistent, once-daily use. The drug works by gradually blocking the acid-producing proton pumps within the stomach lining.


Q: Does taking Nogacid affect my energy levels?

The official safety profile for Nogacid includes reports of nervous system disorders. These may manifest as dizziness, somnolence (sleepiness), or insomnia (difficulty sleeping). Changes to sleep patterns or general alertness could potentially affect a user's perception of their overall energy levels.


Q: Should I avoid certain vitamins or supplements while on Nogacid?

Regulatory documents suggest awareness regarding supplements because long-term omeprazole use has been associated with reduced absorption of Vitamin B12 and low levels of magnesium (Hypomagnesaemia). Information suggests that because of this potential, it is helpful to discuss all vitamin and mineral supplements with a healthcare professional.


Q: Is it safe to take Nogacid if I also take a daily aspirin?

Official information indicates that the active ingredient in Nogacid is sometimes used specifically in combination with aspirin to help reduce the risk of stomach ulcers caused by aspirin. The safety of combining these medications is best determined by a healthcare provider.


Q: Is it normal to feel a bit nauseous when first starting Nogacid?

Nausea is listed as a common side effect in the official product information. This means it has been reported by a measurable number of users and is typically considered a mild effect that may resolve on its own shortly after beginning treatment.


Q: Do I need a prescription to get Nogacid?

The active ingredient in Nogacid (Omeprazole) is available in both prescription-only strengths and over-the-counter (OTC) forms. Regulatory documents indicate that the required strength and intended use determine whether the product is available by prescription or over-the-counter.


Q: Has Nogacid been extensively studied in older patients?

Official prescribing information indicates that generally no dose adjustment is required for older adults. This suggests that this population was included within the drug’s clinical program.


Q: Can taking Nogacid for a long time lead to a B12 deficiency?

Regulatory documents indicate that the potential for reduced absorption of Vitamin B12 from food should be considered. This concern is specifically raised for patients who are receiving long-term treatment with omeprazole.


Q: Is there a generic version of Nogacid available?

Yes. The active ingredient in Nogacid is Omeprazole, which is widely available as a generic medication approved by regulatory agencies.


Q: Can I drink coffee or alcohol while I'm taking Nogacid?

Official drug information usually does not specify a direct chemical interaction between omeprazole and alcohol or coffee. While there is not a specific drug interaction listed, official guidance on managing acid-related conditions often notes that substances like coffee and alcohol can sometimes increase acid production.


Q: Does Nogacid cause changes in bowel habits like diarrhea or constipation?

According to the official safety profile, changes in bowel function are possible. Adverse effects frequently reported include gastrointestinal disorders such as diarrhea and flatulence (gas).


Q: Are there any known interactions between Nogacid and common antibiotics?

The medication is frequently used as part of combination therapy alongside specific antibiotics, such as amoxicillin and clarithromycin, to treat the H. pylori bacteria associated with some ulcers.


Q: Does Nogacid interact with pain relievers like ibuprofen?

There is no direct drug interaction generally reported between omeprazole and pain relievers like ibuprofen. The medication is sometimes used in individuals taking nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen to help reduce the risk of associated stomach ulcers.


Q: Do I need to change my diet while using Nogacid?

Official pharmacokinetic information indicates that omeprazole can affect the absorption of certain nutrients. Furthermore, some food products, such as grape juice, have been shown to reduce the absorption and effectiveness of the medication itself.


Q: How is Nogacid different from similar acid-reducing drugs?

Nogacid belongs to the Proton Pump Inhibitor (PPI) pharmacological class. Its key differentiation is its mechanism of action: it works by irreversibly blocking the final step of acid production, which is a mechanism distinct from other, older classes of acid reducers.


Q: What kind of patient population was Nogacid originally tested on?

Regulatory documents confirm that clinical trials included adult patients for various acid-related conditions, such as GERD and ulcers. The trials also extended to pediatric patients aged one year and older to support the drug's use in younger populations.


Q: Why is it important to know about all drug interactions with Nogacid?

It is important because omeprazole can impact how the body absorbs or metabolizes (breaks down) other medicines. This can lead to the levels of those medicines becoming either too high or too low in the body, potentially affecting their intended action.


Q: Is Nogacid safe for people with pre-existing kidney conditions?

Official information states that a dose adjustment is generally not required for patients with renal impairment (kidney issues). However, reports of rare but serious adverse reactions, such as severe kidney inflammation, have been associated with its use.


Q: How is Nogacid stored to maintain its effectiveness?

Official storage instructions require that the medication be stored at a Controlled Room Temperature, protected from both light and moisture. It must be kept in its tightly closed, original container to maintain its stability.


Q: Are there any food interactions I should be aware of with Nogacid?

Yes, regulatory pharmacokinetic studies indicate that certain food products may interfere with the drug’s absorption. For instance, specific juices, such as grape juice, have been shown to reduce the overall effectiveness of omeprazole.


Q: Can Nogacid cause mouth dryness?

Although not listed as a common side effect in all regulatory documents, there have been published reports noting that reduced salivary flow, which causes a dry mouth, has occurred in some patients treated with omeprazole.


Q: Can Nogacid be taken alongside probiotics?

No specific drug interaction between omeprazole and probiotics is typically reported. However, omeprazole can alter the natural environment of the gut.


Q: Does Nogacid have any effect on blood sugar levels?

Official warnings mention that omeprazole may affect the blood concentration of certain medicines used for diabetes, which belong to the sulfonylurea class. This could potentially increase the risk of low blood sugar (hypoglycemia) in those individuals.


Q: What are the most important warnings listed on the Nogacid label?

Important regulatory warnings focus on long-term use, which is associated with an increased risk of bone fractures (of the hip, wrist, or spine) and the development of Hypomagnesaemia (low magnesium levels). The label also highlights rare but serious reactions such as acute kidney injury.


Q: How long does Nogacid stay in your system after you stop taking it?

While the drug substance itself is cleared from the bloodstream relatively quickly (with a short half-life), its therapeutic effect on acid production is prolonged. The powerful acid-blocking action lasts for approximately 24 hours, until the body can synthesize and replace new proton pumps.

How should Nogacid be stored and disposed of?

Storage and Disposal Requirements

Nogacid (Omeprazole) must be stored under specific conditions to maintain its stability, as documented in official regulatory labeling. Solid dosage forms (capsules/tablets) must be stored at a Controlled Room Temperature, typically 20^circ to 25 C (68^circ to 77 F). The medication requires protection from both light and moisture and should be kept in a tightly closed or original container. Any reconstituted oral suspension, however, requires refrigerated storage at 2^circ to 8 C and must be discarded after 30 days.

Handling and Disposal

The product must be stored out of the reach of children. For disposal, regulatory guidance recommends using a community drug take-back program. If this is unavailable, expired or unused medicine should be mixed with an undesirable substance, placed in a sealed container, and then discarded in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nogacid found in:

A-Z Index: